Back to Journals » Reports in Medical Imaging » Volume 3

Besilesomab for imaging inflammation and infection in peripheral bone in adults with suspected osteomyelitis

Authors Blazeski A, Kozloff K, Scott P

Published 27 August 2010 Volume 2010:3 Pages 17—27

DOI https://doi.org/10.2147/RMI.S9458

Review by Single-blind

Peer reviewer comments 3


Adriana Blazeski1, Kenneth M Kozloff1,2, Peter JH Scott3
1Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA; 2Orthopedic Research Laboratories, Department of Orthopedic Surgery, 3Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, USA
Abstract: Early and accurate diagnosis of osteomyelitis, an inflammatory process of the bone caused by an infective microorganism, is essential for rapid management of the disease by antimicrobial and/or surgical intervention. Historically, diagnosis has been achieved by histological examination, but, more recently, sophisticated molecular imaging techniques (including computed tomography [CT], magnetic resonance imaging, positron emission tomography, single photon emission CT, scintigraphy) that are increasingly used to support diagnoses made from histological data have been reported. For example, scintigraphy has been used to visualize the inflammatory process in vivo using either radiolabeled leukocytes or radiolabeled antigranulocyte monoclonal antibodies (MAbs). Typically, radiolabeling is achieved using technetium-99m (radioactive half-life = 6.02 hours), and the most commonly used MAbs are the Fab fragment of the immunoglobulin (Ig)G antibody directed against the glycoprotein cross-reactive antigen-90 (sulesomab) and an IgG antibody against normal cross-reactive antigen-95 (BW 250/183, besilesomab [Scintimun®]). The aim of the present review is to discuss use of this latter commercially available MAb, besilesomab, for imaging inflammation in adults with suspected osteomyelitis.
Keywords: Scintimun, 99mTc scintigraphy, radiolabeled monoclonal antibodies, BW 250/183, bone infection

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]